Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Rhea-AI Summary
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focused on niche generic products, has scheduled its Q3 FY2025 financial results release for February 13, 2025. The company will host a conference call on February 14, 2025, at 11:30 AM EST to discuss financial and operating results, along with providing a business update.
Stockholders are invited to submit questions prior to the call, with general questions due by February 12, 2025 (5:00 PM EST) and financial questions by February 13, 2025 (7:00 PM EST). The conference call will be accessible via domestic (1-800-346-7359) and international (1-973-528-0008) dial-in numbers using conference number 98840.
Positive
- None.
Negative
- None.
News Market Reaction – ELTP
On the day this news was published, ELTP declined 0.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025
Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2025 fiscal year will be released on Thursday, February 13, 2025. Elite's management will host a live conference call on Friday, February 14th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
| Date: | February 14, 2025 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EST on Wednesday, February 12, 2025 Financial questions by 7:00 PM EST on Thursday, February 13, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240333
FAQ
When will Elite Pharmaceuticals (ELTP) release Q3 FY2025 earnings?
How can investors participate in Elite Pharmaceuticals' (ELTP) Q3 2025 earnings call?
What is the deadline for submitting questions for ELTP's Q3 2025 earnings call?
Where can I find the audio replay of ELTP's Q3 2025 earnings call?
